The Production of Therapeutic Proteins in Plants: Apo AI and Insulin

More documents

Recommendations

Info

Leading Product CandidatesProduct Indication Stage of DevelopmentPharmaceuticalBiosimilar Insulin(SBS-1000)Apo AI MilanoDiabetesAcute CoronarySyndrome(atherosclerosis)Phase I/II• SBS-1000 demonstrated to bebioequivalent to commerciallyavailable insulinPreclinical• Positive preliminaryregression/remodeling data• Pre-IND meeting held Q3 2009
InsulinPositioned to Meet the Growing Demand• Diabetes is a worldwide crisis• Increasing emphasis on earlier use in Type 2 diabetes• Escalating demand in the Developing World will further outstrip supply
Page 1 and 2: The Production of Therapeutic Prote
Page 3 and 4: SemBioSys OverviewLocation: Calgary
Page 5 and 6: SemBioSys’ TechnologyProof-of-Con
Page 7 and 8: Field Grown GMO SafflowerPlanting s
Page 9 and 10: Purification of OilbodiesThe Proces
Page 11 and 12: Plant Impurity AssaysPhytate (IP 6
Page 13 and 14: Product Impurity Assays - Fusion Pa
Page 15: Viral Load/Viral ClearanceRegulator
Page 19 and 20: Economics of Plant-Produced Insulin
Page 21 and 22: Insulin - Equivalence DataV8 Protea
Page 23 and 24: Insulin - Equivalence DataIGF-1 Rec
Page 25 and 26: Insulin Characterization: Clinical
Page 27 and 28: Apo AI Milano (SBS-2000)• FTO - S
Page 29 and 30: Functional Characterization of Puri
Page 31 and 32: Cholesterol Mobilization in vivoSBS
Page 33: Non-Pharma ProductsProducts and Com

The Production of Therapeutic Proteins in Plants: Apo AI and Insulin

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?